JANUX THERAPEUTICS INC (JANX)
Health Care · Cell immunotherapy / T cell engineering · NASDAQ
Clinical-stage biotech developing novel T cell engagers and immunomodulators to treat solid tumors and autoimmune diseases through proprietary TRACTr, TRACIr, and ARM platforms.
What JANUX THERAPEUTICS INC does
Janux Therapeutics is a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies using three proprietary platform technologies: TRACTr (Tumor Activated T Cell Engager), TRACIr (Tumor Activated Immunomodulator), and ARM (Adaptive Immune Response Modulator). The company's lead program, JANX007, is a PSMA-targeted T cell engager in Phase 1 trials for metastatic castration-resistant prostate cancer. Janux is advancing multiple clinical candidates including JANX014 and JANX013 for oncology, and JANX011 for autoimmune diseases, with the goal of creating safer and more effective cancer immunotherapies that minimize toxicity while maintaining anti-tumor activity.
Themes: ["oncology / solid tumors","immuno-oncology","T cell engagers","immunotherapy","prostate cancer","autoimmune diseases","cell therapy"]
Fundamentals
- Price$16.75 as of 2026-07-09 close
- Market cap$1.0B as of 2026-07-10
- 1-year return-31.9% as of 2026-07-09 close
- Net margin-354.4% as of 2026-07-10
- ROE-11.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+47.1% as of 2026-07-10
- Beta2.53 as of 2026-07-10
Key risks (from latest filing)
["All product candidates are in clinical or preclinical stages with no approved products; development, regulatory approval, and commercialization timelines are uncertain and may not succeed.","Company is unprofitable and has never generated product revenue; continued funding via capital raises and potential collaborations required to support ongoing R&D and clinical trials.","T cell engager technologies face inherent safety challenges including cytokine release syndrome and on-target healthy tissue toxicity; prior-generation TCE programs have shown limited efficacy in solid tumors."]
Competitors & peers
- Juno Therapeutics
- Tmunity Therapeutics
- Autolus Therapeutics
- Forty Seven Inc.
- TCR2 Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.